Remgro Limited provided earnings guidance for the six months ended December 31, 2013. For the period, the company headline earnings per share is expected to be between 18% and 22% higher than the restated HEPS of the comparative six months ended December 31, 2012. Excluding the effect of the once-off items relating to Mediclinic's refinancing transaction, Remgro's HEPS for the six months ended December 31, 2013 is expected to be between 18% and 22% higher than the restated HEPS of the comparative six months ended December 31, 2012.

Prior to the restatement of the comparative results for the six months ended December 31, 2012, Remgro's reported HEPS is expected to be between 111% and 115% higher than the HEPS of the six months ended 31 December 2012. Excluding the effect of the once-off items relating to Mediclinic's refinancing transaction and also prior to the restatement of the comparative results, Remgro's HEPS for the six months ended 31 December 2013 is expected to be between 14% and 18% higher than the HEPS of the six months ended 31 December 2012.